OTCMKTS:PXXLF - Poxel Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$8.16
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Poxel Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PXXLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PXXLF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Poxel in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.16.
Buy
The current consensus among 1 polled investment analysts is to buy stock in Poxel.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
6/23/2020JMP SecuritiesInitiated CoverageOutperform
i
(Data available from 2/28/2016 forward)
Poxel logo
Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.
Read More

Today's Range

Now: $8.16
$8.16
$8.16

50 Day Range

MA: $8.17
$8.16
$8.17

52 Week Range

Now: $8.16
$6.03
$15.35

Volume

N/A

Average Volume

9,613 shs

Market Capitalization

$196.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Poxel?

The following Wall Street sell-side analysts have issued research reports on Poxel in the last year: JMP Securities, and Zacks Investment Research.
View the latest analyst ratings for PXXLF.

What is the current price target for Poxel?

0 Wall Street analysts have set twelve-month price targets for Poxel in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Poxel in the next year.
View the latest price targets for PXXLF.

What is the current consensus analyst rating for Poxel?

Poxel currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PXXLF will outperform the market and that investors should add to their positions of Poxel.
View the latest ratings for PXXLF.

What other companies compete with Poxel?

How do I contact Poxel's investor relations team?

Poxel's physical mailing address is 259-261 Avenue Jean Jaures, Lyon I0, 69007. The company's listed phone number is 33-4-37-37-20-10 and its investor relations email address is [email protected] The official website for Poxel is www.poxel.com.